(firstQuint)Versartis International Trial in Adults With Long-Acting Growth Hormone.

 A Phase 2, dose finding safety study to evaluate an individualized monthly VRS-317 dosing regimen in adults with GHD.

 This is an open-label, international, multicenter study with VRS-317 treatment for five months.

 This treatment period will include monthly dose titrations until a subject's mean IGF-I SDS value is within a target range for two consecutive months.

 Subjects will be stratified into three cohorts based on sensitivity to rhGH.

.

 Versartis International Trial in Adults With Long-Acting Growth Hormone@highlight

A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.

